Hyloris Pharmaceuticals (HYL) H2 2025 earnings summary

Executive summary

• Royalty income grew 15% year-over-year to €5.6 million, led by MaxigesicⓇ IV and Sotalol IV, despite currency headwinds and Podofilox Gel stock-out issues.

• Total operating income declined 12% to €8.8 million due to lower non-recurring milestone revenue and adverse FX effects.

• Portfolio expanded to over 30 assets, with six new product additions and eight new out-licensing agreements in 2025.

• Net loss remained stable at €6.3 million, reflecting disciplined cost management amid increased R&D investment.

• Cash position at year-end was €13.8 million, with no financial debt.

Financial highlights

• Royalty income: €5.6 million (+15% YoY); recurring revenues (royalties + product sales): €5.9 million (+20% YoY).

• Milestone income: €1.4 million, down 62% YoY due to a large one-off milestone in 2024; excluding this, decline was 14%.

• Total revenues: €7.2 million (–15% YoY); operating income: €8.8 million (–12% YoY).

• Operating expenses decreased 9% to €15.6 million; R&D expenses rose to €11.3 million (+10% YoY).

• Net loss: €6.3 million (unchanged YoY); equity: €26.5 million (–18% YoY).

• Cash and cash equivalents: €13.8 million (–42% YoY).

Outlook and guidance

• Continued advancement of the development portfolio and strategic growth opportunities supported by strong cash position.

• U.S. commercial promotion for MaxigesicⓇ IV expected to intensify from late Q2 2026.

• Multiple regulatory submissions and clinical trial completions anticipated in 2026.